GlaxoSmithKline Consumer Healthcare Ltd. - Research Center
GSKCONS Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | Mar ' 15 | |
|---|---|---|---|---|---|
| Sales | 4,782.01 | 4,316.51 | 3,986.46 | 4,136.27 | 4,307.59 |
| Operating profit | 1,140.97 | 883.35 | 833.49 | 838.16 | 730.08 |
| Interest | 0.78 | 2.03 | 2.78 | 2.28 | 0.74 |
| Gross profit | 1,572.79 | 1,138.73 | 1,074.59 | 1,113.39 | 951.23 |
| EPS (Rs) | 233.67 | 166.45 | 156.13 | 163.40 | 138.77 |
Annual
results in details
| Mar ' 19 | Mar ' 18 | Mar ' 17 | Mar ' 16 | Mar ' 15 | |
|---|---|---|---|---|---|
| Other income | 432.60 | 257.41 | 243.88 | 277.51 | 221.89 |
| Stock adjustment | -58.92 | 40.98 | -7.66 | -2.70 | -42.97 |
| Raw material | 1,380.30 | 1,251.96 | 1,150.75 | 1,221.76 | 1,378.87 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 644.62 | 527.73 | 458.03 | 504.98 | 431.29 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | 602.25 | 546.73 | 514.67 | 544.09 | 717.08 |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,072.79 | 1,065.76 | 1,037.18 | 1,029.98 | 1,093.24 |
| Provisions made | - | - | - | - | - |
| Depreciation | 60.50 | 64.37 | 64.18 | 57.44 | 62.09 |
| Taxation | 529.49 | 374.26 | 353.74 | 368.67 | 305.54 |
| Net profit / loss | 982.80 | 700.10 | 656.67 | 687.28 | 583.60 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 42.06 | 42.06 | 42.06 | 42.06 | 42.06 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | 115.84 |
| Agg.of non promotoholding (%) | - | - | - | - | 27.54 |
| OPM (%) | 23.86 | 20.46 | 20.91 | 20.26 | 16.95 |
| GPM (%) | 30.16 | 24.90 | 25.40 | 25.23 | 21.00 |
| NPM (%) | 18.85 | 15.31 | 15.52 | 15.57 | 12.88 |
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis